trending Market Intelligence /marketintelligence/en/news-insights/trending/bs07oxgvz7k9tieoqzglda2 content esgSubNav
In This List

Regenxbio closes common stock offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Regenxbio closes common stock offering

Regenxbio Inc. closed an underwritten public offering of 2,700,000 common shares, priced $65 each.

The Rockville, Md.-based developer of gene therapies raised gross proceeds of about $201.8 million.

Underwriters fully exercised their option to buy 405,000 additional shares at the offering price.

Morgan Stanley, Bank of America Merrill Lynch and Barclays acted as joint book-running managers for the offering, with Raymond James as co-manager.